| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Mar―26 |
Placental Ferroptosis and Impaired Fetal Growth in Symptomatic and Asymptomatic SARS-CoV-2 Infections |
Yusmaris Cariaco, Abolfazl Nik-Akhtar, Marie-Eve Brien, Keir Menzies, Sylvie Girard, Shannon Bainbridge |
| 2 |
[GO] |
2025―Nov―17 |
Annexin A1 as a key modulator of lung inflammation during coronavirus infections |
Filipe Resende, Celso Martins Queiroz-Junior, Fernando Roque Ascenção, Ian de Meira Chaves, Larisse de Souza Barbosa Lacerda, Felipe Rocha, Danielle Teixeira, Izabela Galvão, Victor Costa, Talita Fonseca, Arthur Gualberto, Ana Luiza de Castro Santos, Jenniffer Martins, Erick Bryan de Sousa Lima, Adelson Héric Alves Monteiro, Isabella Zaidan, Laís C. Grossi, Pedro Augusto Carvalho Costa, Vinicius Amorim Beltrami, Lirlândia P. Sousa, Pedro Pires Goulart Guimarães, Gabriel Campolina-Silva, Mauro M. Teixeira, Vanessa Pinho, Vivian V. Costa |
| 3 |
[GO] |
2025―Jun―05 |
Dysregulation of NK cell subsets and phenotypes in COVID-19 patients with comorbid type 2 diabetes |
Kang Lei, Wenqi Fan, Ting Zhong, Xinyu Li, Rong Tang, Bin Zhao, Xia Li |
| 4 |
[GO] |
2024―Dec―12 |
Harnessing 2D and 3D human endometrial cell culture models to investigate SARS-CoV-2 infection in early pregnancy. |
Madhuri Salker, Anna Liu, Natalia Ruetalo, Janet Pushpa Raja Xavier, Aditya Kumar Lankapalli, Jakob Admard, Miguel Camarena-Sainz, Sara Brucker, Yogesh Singh, Michael Schindler |
| 5 |
[GO] |
2024―Apr―04 |
Correction: The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease |
|
| 6 |
[GO] |
2024―Feb―19 |
COVID-19 and abnormal uterine bleeding: potential associations and mechanisms |
Jacqueline A. Maybin, Marianne Watters, Bethan Rowley, Catherine A. Walker, Gemma C. Sharp, Alexandra Alvergne |
| 7 |
[GO] |
2022―Nov―11 |
Vascular dysfunction in COVID-19 patients: update on SARS-CoV-2 infection of endothelial cells and the role of long non-coding RNAs |
Jaroslav Pelisek, Benedikt Reutersberg, Urs F Greber, Alexander Zimmermann |
| 8 |
[GO] |
2022―Oct―21 |
Therapeutic use of calpeptin in COVID-19 infection |
Jameel Inal, Ainura Paizuldaeva, Esmeralda Terziu |
| 9 |
[GO] |
2022―Jul―06 |
Casting a wide NET: an update on uncontrolled NETosis in response to COVID-19 infection |
Erin B. Taylor |
| 10 |
[GO] |
2022―Mar―29 |
SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection |
John D. Imig |
| 11 |
[GO] |
2021―Dec―08 |
Erythrocytes increase endogenous sphingosine 1-phosphate (S1P) levels as an adaptive response to SARS-CoV-2 infection |
Martin Sebastian Winkler, Ralf A Claus, Mareike Schilder, Stefan Pöhlmann, Sina Coldewey, Julian Grundmann, Torben Fricke, Onnen Moerer, Konrad Meissner, Michael Bauer, Heike Hofmann-Winkler, Markus Gräler |
| 12 |
[GO] |
2021―Nov―22 |
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147-receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease |
Elisa Avolio, Michele Carrabba, Rachel Milligan, Maia Kavanagh Williamson, Antonio Beltrami, Kapil Gupta, Karen T Elvers, Monica Gamez, Rebecca Foster, Kathleen Gillespie, Fergus Hamilton, David Arnold, Imre Berger, Andrew Davidson, Darryl J. Hill, Massimo Caputo, Paolo Madeddu |
| 13 |
[GO] |
2021―Aug―02 |
Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility |
Nayara Azinheira Nobrega Cruz, Danielle Stoll, Dulce Elena Casarini, Mariane Bertagnolli |
| 14 |
[GO] |
2021―Apr―21 |
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? |
Fedor Simko, Tomas Baka |
| 15 |
[GO] |
2021―Feb―06 |
ACE2 and energy metabolism: the connection between COVID-19 and chronic metabolic disorders |
Xi Cao, Li-Ni Song, Jin-Kui Yang |
| 16 |
[GO] |
2021―Jan―29 |
ACE2/Ang-(1-7)/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease |
Jithin Kuriakose, Augusto C. Montezano, Rhian M. Touyz |
| 17 |
[GO] |
2021―Jan―23 |
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19 |
Maria A Pedrosa, Rita Valenzuela, Pablo Garrido, Carmen M Labandeira, Gemma Navarro, Rafael Franco, Jose Luis Labandeira-Garcia, Ana I Rodriguez-Perez |
| 18 |
[GO] |
2021―Jan―07 |
Angiotensin-converting enzyme 2 and COVID-19 in cardiorenal diseases |
Ravindra K. Sharma, Jing Li, Suraj Krishnan, Elaine M. Richards, Mohan K. Raizada, Rajesh Mohandas |
| 19 |
[GO] |
2020―Dec―11 |
ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19 |
Michael Bader, Anthony J. Turner, Natalia Alenina |
| 20 |
[GO] |
2020―Dec―09 |
ACE2: from protection of liver disease to propagation of COVID-19 |
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath |
| 21 |
[GO] |
2020―Dec―03 |
Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists |
U. Muscha Steckelings, Colin Sumners |
| 22 |
[GO] |
2020―Nov―25 |
ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19 |
Koichi Yamamoto, Hikari Takeshita, Hiromi Rakugi |
| 23 |
[GO] |
2020―Nov―04 |
ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV |
Lizelle Lubbe, Gyles E. Cozier, Delia Oosthuizen, K. Ravi Acharya, Edward D. Sturrock |
| 24 |
[GO] |
2020―Nov―02 |
ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery |
Enrique Lores, Jan Wysocki, Daniel Batlle |
| 25 |
[GO] |
2020―Oct―16 |
Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease |
Carlos M. Ferrario, Sarfaraz Ahmad, Leanne Groban |
| 26 |
[GO] |
2020―Sep―29 |
Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19 |
Nigel M. Hooper, Daniel W. Lambert, Anthony J. Turner |
| 27 |
[GO] |
2020―Sep―09 |
Correction: Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission |
|
| 28 |
[GO] |
2020―Sep―01 |
Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera |
Mohamad Aman Jairajpuri, Shoyab Ansari |
| 29 |
[GO] |
2020―Aug―21 |
Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission |
Daniella S. Battagello, Guilherme Dragunas, Marianne O. Klein, Ana L.P. Ayub, Fernando J. Velloso, Ricardo G. Correa |
| 30 |
[GO] |
2020―Aug―04 |
Suppressed anti-inflammatory heat shock response in high-risk COVID-19 patients: lessons from basic research (inclusive bats), light on conceivable therapies |
Thiago Gomes Heck, Mirna Stela Ludwig, Matias Nunes Frizzo, Alberto Antonio Rasia-Filho, Paulo Ivo Homem de Bittencourt |
| 31 |
[GO] |
2020―Jun―16 |
Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy |
Jameel M. Inal |
| 32 |
[GO] |
2020―Jun―16 |
SARS-CoV2 may evade innate immune response, causing uncontrolled neutrophil extracellular traps formation and multi-organ failure |
Alain R. Thierry, Benoit Roch |
| 33 |
[GO] |
2020―Jun―08 |
Covid-19: the renin-angiotensin system imbalance hypothesis |
Katharina Lanza, Lucas G. Perez, Larissa B. Costa, Thiago M. Cordeiro, Vitria A. Palmeira, Victor T. Ribeiro, Ana Cristina Simões e Silva |
| 34 |
[GO] |
2020―May―22 |
Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs |
Sayeed ur Rehman, Mohammad Tabish |
| 35 |
[GO] |
2020―Apr―07 |
ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19 |
Rhian M. Touyz, Hongliang Li, Christian Delles |
| 36 |
[GO] |
2020―Mar―13 |
Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? |
Daniel Batlle, Jan Wysocki, Karla Satchell |
